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Introduction {#sec1}
============

Malaria represents a major cause of death from infectious disease, resulting in 216 million new cases and an estimated 445,000 deaths in 2016 ([@bib49]). The disease is caused by infection with obligate intraerythrocytic apicomplexan parasites of the genus *Plasmodium*. *P. falciparum* represents a major morbidity factor due to the development of severe malaria; e.g., cerebral malaria ([@bib29]). Infection of susceptible mice with *Plasmodium berghei* Antwerpen-Kasapa (ANKA) (PbA) is a commonly accepted model for *Plasmodium*-induced inflammation. Experimental cerebral malaria (ECM) pathology induced by PbA infection encompasses neurovascular inflammation with neurological symptoms such as cognitive dysfunction, ataxia, paralysis, convulsions, and coma, ultimately leading to death ([@bib7]).

Immunopathology during PbA infection has been extensively studied. ECM is predominantly mediated by brain-sequestered T cells ([@bib2], [@bib11], [@bib13], [@bib14], [@bib50]). CD8^+^ T cells in particular are crucial for ECM pathogenesis by release of perforin and granzyme B (GrB), promoting tissue damage and compromising blood-brain barrier integrity ([@bib12], [@bib31], [@bib36]). Naive T cells are primed by conventional CD11c^+^ dendritic cells (DCs) in the spleen (cross)presenting PbA-derived antigens; thus, DCs contribute to T cell-mediated pathology during malaria ([@bib8]).

Besides brain-sequestered T cells, a pro-inflammatory cytokine milieu is linked to the disease that is believed to be provoked by *Plasmodium*-derived hemozoin. Hemozoin crystals constitute a disposal product generated during intra-erythrocytic parasite development. After infection of red blood cells (RBCs), the parasite consumes up to 80% of the hemoglobin and crystallizes otherwise toxic heme monomers into insoluble hemozoin ([@bib6]). Hemozoin crystals are released during host cell rupture and rapidly ingested by phagocytes with subsequent production of pro-inflammatory cytokines, nitric oxide (NO), and reactive oxygen species (ROS) at the early onset of disease ([@bib33], [@bib42], [@bib47]). For instance, hemozoin is known to induce activation of the NLRP3/inflammasome complex via potassium efflux, phagocytosis, and ROS production, leading to release of the pro-inflammatory cytokine interleukin-1β (IL-1β) ([@bib9], [@bib41]). Fatal malaria cases are characterized by increased numbers of monocytes and neutrophils carrying intracellular hemozoin deposits ([@bib30]). ECM-susceptible mice infected with PbA exhibit significantly increased levels of hemozoin in the brain, in contrast to mice infected with the non-ECM-inducing *P. berghei* strain NK65 ([@bib43]). Hence, although hemozoin has been shown to be immunologically active *in vitro* and *in vivo*, the cellular receptors recognizing hemozoin remain elusive.

It has been shown that pattern recognition receptors (PRRs) such as Nod-like receptors (NLRs) are important mediators of ECM pathogenesis *in vivo* ([@bib9]), whereas the role of Toll-like receptors (TLRs) in ECM development is debated ([@bib5], [@bib22], [@bib45]). TLR2 and TLR4 recognize *P. falciparum* glycosylphosphatidyl inositol (GPI) anchors, thus mediating cytokine and NO production ([@bib18]). Additionally, TLR9 senses CpG and adenine thymine (AT) motifs in plasmodial DNA present on the surface of *Plasmodium*-derived hemozoin ([@bib34]). In contrast, there is a gap of knowledge regarding the contribution of C-type lectin receptors (CLRs) to immunity during the course of malaria. The F-Actin-recognizing CLR CLEC9A defines a DC subset that is crucial for ECM development via cross-priming of CD8^+^ T cells ([@bib35]). We have shown previously that the DC immunoreceptor (DCIR) markedly alters the course of disease since DCIR^−/−^ mice are significantly protected from ECM ([@bib24]). However, direct recognition of a *Plasmodium*-derived ligand by CLRs has so far not been shown.

The myeloid inhibitory C-type lectin-like receptor (CLEC12A) is a type II transmembrane protein predominantly expressed by innate immune cells such as granulocytes, macrophages, and DCs ([@bib19], [@bib37]). CLEC12A can be exploited to deliver tumor antigens into DCs, inducing efficient activation of CD8^+^ T cells by cross-priming ([@bib15]), and can be efficiently targeted to induce influenza antigen-specific tissue-resident memory CD8^+^ T cells ([@bib48]). A recent study identified monosodium urate (MSU) crystals as a CLEC12A ligand, highlighting an important role of CLEC12A in recognition of dead cells. In this context, CLEC12A is critically involved in the MSU-mediated respiratory burst by interfering with Syk signaling ([@bib28]).

To identify *Plasmodium*-derived CLR ligands, we employed a CLR-human Fc (hFc) fusion protein library ([@bib25], [@bib26]) and observed strong binding of CLEC12A-hFc to parasitized RBC (pRBC)-derived lysates and permeabilized pRBCs. Reporter cell assays, flow cytometry-based assays, and fluorescence microscopy revealed hemozoin crystals as a CLEC12A ligand. Hemozoin affected ROS production by bone marrow-derived DCs (BMDCs) and ovalbumin (OVA)~257--264~ peptide cross-presentation by BMDCs to OT-I T cell receptor (TCR)-transgenic T cells in a CLEC12A-dependent fashion. *In vivo* challenge of CLEC12A^−/−^ mice with PbA resulted in reduced ECM incidence and attenuated ECM symptoms, accompanied by reduced expression of granzyme B in T cells derived from brains and spleens of infected mice. Taken together, this study provides a mechanism by which hemozoin is recognized by innate immunity and reveals an important role of CLEC12A in immunopathology during malaria.

Results {#sec2}
=======

CLEC12A Recognizes Hemozoin {#sec2.1}
---------------------------

We demonstrated previously that DCIR plays a crucial role in ECM development ([@bib24]). However, DCIR does not bind to parasite-derived ligands but, rather, recognizes endogenous damage-associated molecular patterns (DAMPs; [@bib1]). Thus, to identify CLR interactions with *Plasmodium*-derived ligands, we employed a CLR-hFc fusion protein library ([@bib25], [@bib26]). Initial screenings were carried out using *P. falciparum*-infected RBCs. We observed marked binding for CLEC12A-hFc as opposed to the hFc control or other CLR-hFc chimeras, such as DCIR-hFc, DC immunoactivating receptor (DCAR)-hFc, macrophage C-type lectin (MCL)-hFc, and CLEC9A-hFc ([Figure 1](#fig1){ref-type="fig"}A). Binding was confirmed using PbA pRBCs ([Figure 1](#fig1){ref-type="fig"}B), indicating that CLEC12A recognizes a plasmodial component present in different *Plasmodium* species. To identify whether CLEC12A recognizes an intracellular component within *Plasmodium*-infected RBCs, we analyzed binding to pRBCs by fluorescence microscopy upon RBC permeabilization. Indeed, CLEC12A-hFc specifically bound to permeabilized pRBCs, suggesting that CLEC12A recognizes an internal ligand present in pRBCs ([Figure 1](#fig1){ref-type="fig"}C).Figure 1CLEC12A Recognizes Hemozoin(A and B) ELISA-based binding studies with (A) *P. falciparum* and (B) *P. berghei* ANKA. Isolated parasitized RBCs (pRBCs) were lysed, immobilized on microtiter plates, and probed with the indicated fusion proteins. Lysates from uninfected RBCs (uRBCs) and PBS alone (control) were used as controls. Data are presented as mean + SEM and representative of three independent experiments in duplicates for *P. falciparum* (n = 3) and two experiments in duplicates for *P. berghei* ANKA (n = 2).(C) Fluorescence microscopy of permeabilized pRBCs. Permeabilized pRBCs were incubated with CLEC12A-hFc, followed by staining with an anti-human immunoglobulin G (IgG) (Fc) Alexa Fluor 488-labeled antibody (AF488, green). Parasitic DNA was stained with DAPI (blue). Hemozoin fluorescence was visualized using a 633-nm HeNe laser (hemozoin, red). pRBCs probed with hFc served as a negative control. Data are representative of two independent experiments (n = 2). Scale bars represent 1 μm.(D) Flow cytometry-based binding studies with hemozoin. Hemozoin was probed with the indicated fusion proteins. CLEC7A-hFc served as a negative control. Means + SD of three independent experiments (n = 3) are shown.(E) Fluorescence microscopy of synthetic hemozoin. Hemozoin was probed with the indicated hFc fusion proteins and incubated with an anti-human IgG (Fc) Alexa Fluor 488 antibody (AF488, green). Samples incubated with hFc served as a negative control. Data are representative of two independent experiments (n = 2). Scale bars represent 10 μm.(F) Recognition of hemozoin (100 μg/mL) and MSU (250 μg/mL) by human (h) and murine (m) CLEC12A-CD3 reporter cell lines. A murine CLEC7A-CD3 reporter cell line served as a negative control. Data are presented as mean + SD and are representative of three independent experiments (n = 3) in triplicates (two experiments) or quadruplicates (one experiment).Statistical significance was evaluated using unpaired (ELISA, reporter cell assay) or paired (flow cytometry-based binding studies) two-tailed Student's t test. Asterisks indicate significant differences (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Because CLEC12A was recently shown to bind to uric acid crystals ([@bib28]), we hypothesized that this CLR might be involved in the recognition of hemozoin crystals. Although many protocols for the synthesis of hemozoin yield material that is poorly crystalline ([@bib17]), we used synthetic hemozoin that resembled natural hemozoin in size (0.5--1 μm), as confirmed by electron microscopy ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Indeed, both human CLEC12A-hFc as well as murine CLEC12A-hFc bound to synthetic hemozoin, as demonstrated by flow cytometry ([Figure 1](#fig1){ref-type="fig"}D) and fluorescence microscopy ([Figure 1](#fig1){ref-type="fig"}E). To analyze whether hemozoin acts as an agonistic ligand of CLEC12A, reporter cell assays were performed. Because binding of MSU to the CLEC12A reporter cell line has been demonstrated previously ([@bib28]), MSU was used as a positive control. Hemozoin showed marked activation of cells expressing human CLEC12A and, to a lower extent, murine CLEC12A ([Figure 1](#fig1){ref-type="fig"}F). Even lysates of *Plasmodium*-infected RBCs induced activation of CLEC12A reporter cells compared with uninfected RBCs, indicating that hemozoin can be recognized by CLEC12A at physiological concentrations ([Figure S1](#mmc1){ref-type="supplementary-material"}B). These findings clearly show that hemozoin acts as an agonistic ligand of the CLR CLEC12A.

CLEC12A Impairs DC Effector Functions *In Vitro* {#sec2.2}
------------------------------------------------

CLEC12A is mainly expressed by DCs ([@bib19]). Therefore, we assessed the effect of the hemozoin/CLEC12A interaction on DC effector functions by stimulating BMDCs from CLEC12A^−/−^ and wild-type (WT) mice with hemozoin. Hemozoin is known to interfere with ROS production of antigen-presenting cells (APCs), depending on the stimulation conditions ([@bib3], [@bib39], [@bib42]). Hence, BMDCs were stimulated with hemozoin for 4 h or 24 h, followed by ROS induction using phorbol 12-myristate-13-acetate (PMA). Hemozoin slightly reduced the capacity to produce ROS after 4 h and strongly after 24 h incubation in both WT and CLEC12A^−/−^ BMDCs. Strikingly, reduction of ROS production was more pronounced in CLEC12A^−/−^ BMDCs (ROS activity after 4 h: WT 90.2%, CLEC12A^−/−^ 78.1%; ROS activity after 24 h: WT 34.4%, CLEC12A^−/−^ 25.0%), indicating that hemozoin-impaired ROS production is at least partially CLEC12A dependent ([Figure 2](#fig2){ref-type="fig"}A). Interestingly, we did not observe differences in overall hemozoin internalization by DCs, indicating that CLEC12A did not act as a phagocytic receptor (data not shown). To assess whether the CLEC12A/hemozoin interaction had an effect on antigen uptake and processing, BMDCs were stimulated with Alexa Fluor 488-labeled OVA (to assess antigen uptake) or DQ OVA (to measure antigen processing) in the presence or absence of hemozoin. OVA uptake and processing were not impaired by the CLEC12A/hemozoin interaction ([Figures 2](#fig2){ref-type="fig"}B and 2C). Additional DC effector functions were monitored by stimulating BMDCs in the presence or absence of hemozoin. However, no differences were observed in pro-inflammatory cytokine secretion ([Figure S2](#mmc1){ref-type="supplementary-material"}A) or expression of activation markers ([Figure S2](#mmc1){ref-type="supplementary-material"}B) between WT and CLEC12A^−/−^ BMDCs. These findings indicate that the CLEC12A/hemozoin interaction selectively affected ROS production by BMDCs.Figure 2Hemozoin Recognition by CLEC12A Affects DC Effector Functions(A) CLEC12A^−/−^ or wild-type (WT) bone marrow-derived dendritic cells (BMDCs) were treated with hemozoin (100 μg/mL) for 4 h or 24 h, respectively. After hemozoin stimulation, ROS production was induced by stimulation with PMA (100 ng/mL) and evaluated using DHR-123.(B and C) CLEC12A^−/−^ or WT BMDCs were pulsed with (B) Alexa Fluor 488-labeled ovalbumin (OVA-AF488) (25 μg/mL) to assess antigen uptake or (C) DQ OVA (25 μg/mL) to measure antigen processing.All data are representative of three experiments (n = 3) in triplicates, displayed as mean + SD and expressed as percentages to control after normalization to the mean fluorescence intensities of the respective samples stimulated with PMA or OVA only. Statistical analysis was performed using unpaired two-tailed Student's t test. Asterisks indicate significant differences (^∗^p \< 0.05, ^∗∗^p \< 0.01). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

CLEC12A Affects T Cell Activation *In Vitro* {#sec2.3}
--------------------------------------------

To unravel the CLEC12A/hemozoin interaction on DCs and subsequent T cell priming mechanistically, antigen presentation assays using BMDCs from CLEC12A^−/−^ mice and WT control mice were conducted. Because CD8^+^ T cells play a pivotal role in ECM induction, the CD8^+^ T cell response to cross-presented OVA~257--264~ peptide was measured using OT-I TCR-transgenic CD8^+^ T cells. To this end, cytokine release by OT-I CD8^+^ T cells was measured by ELISA, and intracellular cytokine accumulation was determined by flow cytometry (see [Figure S3](#mmc1){ref-type="supplementary-material"}A for gating of cells). Upon OVA stimulation alone, cytokine secretion and frequency of cytokine-producing T cells were slightly higher when T cells were co-cultured with CLEC12A^−/−^ BMDCs, consistent with the putative role of CLEC12A as an inhibitory receptor. Thus, to exclude intrinsic hemozoin-independent effects, data were normalized to stimulation with OVA only. Hemozoin enhanced CD8^+^ T cell responses, as indicated by increased production of GrB, IL-2, tumor necrosis factor alpha (TNF-α), and interferon γ (IFN-γ) as well as an elevated number of cytokine-positive T cells ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}B). However, hemozoin-enhanced IL-2 production was completely abolished, GrB production reduced, and TNF-α production slightly reduced when CLEC12A^−/−^ BMDCs were used to stimulate OT-I T cells. Similar effects were observed for the number of cytokine-expressing T cells ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These findings highlight involvement of CLEC12A in cross-presentation of antigens. A similar effect was found for expression of the T cell activation marker CD69 ([Figure S3](#mmc1){ref-type="supplementary-material"}C). In contrast, only minor effects of the CLEC12A/hemozoin interaction on cytokine production by OT-II TCR-transgenic CD4^+^ T cells (activated by the OVA~323--339~ peptide) were observed ([Figure 3](#fig3){ref-type="fig"}B). Taken together, DC-T cell co-cultures show that the stimulatory effect of the CLEC12A/hemozoin interaction is mainly restricted to cross-priming of CD8^+^ T cells.Figure 3Hemozoin Recognition by CLEC12A Affects CD8^+^ T Cell PrimingCLEC12A^−/−^ or WT BMDCs were pulsed with EndoGrade OVA (300 μg/mL) in the presence or absence of hemozoin. BMDCs were co-cultured with either OT-I or OT-II receptor transgenic T cells. Anti-CD3 (5 μg/mL)-stimulated T cells served as a positive control.(A) OT-I CD8^+^ T cell secretion of granzyme B (GrB), IL-2, TNF-α, and IFN-γ. Mean cytokine production of samples stimulated with OVA only ranged from 1,470 pg/mL (WT) to 2,308 pg/mL (CLEC12A^−/−^) for GrB, 106 pg/mL (WT) to 133 pg/mL (CLEC12A^−/−^) for IL-2, 104 pg/mL (WT) to 119 pg/mL (CLEC12A^−/−^) for TNF-α, and 1,022 pg/mL (WT) to 866 pg/mL (CLEC12A^−/−^) for IFN-γ.(B) OT-II CD4^+^ T cell secretion of GrB, IL-2, TNF-α, and IFN-γ. Mean cytokine production of samples stimulated with OVA only ranged from 502 pg/mL (WT) to 448 pg/mL (CLEC12A^−/−^) for GrB, 427 pg/mL (WT) to 490 pg/mL (CLEC12A^−/−^) for IL-2, 88 pg/mL (WT) to 100 pg/mL (CLEC12A^−/−^) for TNF-α, and 465 pg/mL (WT) to 342 pg/mL (CLEC12A^−/−^) for IFN-γ.Graphs are representatives of two (OT-I, n = 2) and three (OT-II, n = 3) independent experiments in triplicates. All data were normalized to the respective OVA stimulation, expressed as fold change and displayed as mean + SD. Statistical significance was evaluated using unpaired two-tailed Student's t test. Asterisks indicate significant differences (^∗^p \< 0.05, ^∗∗^p \< 0.01). n.d., not detectable. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

CLEC12A Contributes to ECM Development and Affects Granzyme B Expression by T Cells {#sec2.4}
-----------------------------------------------------------------------------------

The marked effect of the CLEC12A/hemozoin interaction on CD8^+^ T cell priming *in vitro* prompted us to evaluate the role of CLEC12A *in vivo*. Therefore, we challenged CLEC12A^−/−^ mice with PbA and assessed ECM pathogenesis. As expected, WT mice displayed neurological symptoms within 7--10 days post infection (p.i.) with a total ECM incidence of around 90%. Strikingly, CLEC12A^−/−^ mice were significantly protected from ECM, enhancing the final survival rate after 14 days by 42% compared with WT mice (52% versus 10%; [Figure 4](#fig4){ref-type="fig"}A). Consistent with these findings, CLEC12A^−/−^ mice showed a significantly reduced disease score over time ([Figure 4](#fig4){ref-type="fig"}B). No significant differences were observed regarding parasitemia levels between CLEC12A^−/−^ and WT control mice, suggesting that CLEC12A deficiency does not affect parasite replication directly ([Figure S4](#mmc1){ref-type="supplementary-material"}A).Figure 4CLEC12A Deficiency Protects from ECM Development(A and B) CLEC12A^−/−^ and C57BL/6 control mice were challenged with PbA by intraperitoneal injection of 1 × 10^6^ pRBCs and monitored for up to 14 days. The illustrated plots are summarized from three independent experiments (WT: n = 10, 4, 4; total n = 18 mice; CLEC12A^−/−^: n = 9, 5, 5; total n = 19 mice). Statistical analysis was performed using log rank test (survival) or two-way repeated measures ANOVA (disease score).(A) Survival of CLEC12A^−/−^ mice compared with WT animals. Mice were euthanized at an early stage of ECM to minimize suffering (see [STAR Methods](#sec4){ref-type="sec"} for details).(B) Disease score values reflecting the presence of symptoms. For each following day post sacrifice, a score of 5 was assigned. Data are expressed as mean ± SEM.(C and D) PbA-infected CLEC12A^−/−^ and C57BL/6 control mice were sacrificed on day 6 p.i., followed by flow cytometry measurement of GrB expression. Data are expressed as mean + SEM and summarized from two independent experiments (n = 3, 5; total n = 8 mice).(C) Representative plots illustrating the frequency of GrB-expressing CD8^+^ T cells in the brain with corresponding statistical analysis of GrB^+^ CD8^+^ T cells in the brain. Statistical analysis was performed using unpaired one-tailed Student's t test.(D) Statistical analysis illustrating the frequency of splenic GrB-expressing CD4^+^ and CD8^+^ T cells. Statistical analysis was performed using unpaired two-tailed Student's t test.Asterisks indicate significant differences (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001). See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To analyze systemic inflammation, pro-inflammatory serum cytokines were measured in PbA-infected CLEC12A^−/−^ and WT mice. Overall, PbA infection enhanced the levels of TNF-α, IFN-γ, and IL-6. However, systemic inflammation was not altered in CLEC12A^−/−^ mice compared with WT mice ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Quantitative T cell sequestration to the brain was not significantly altered in CLEC12A^−/−^ mice despite a tendency toward reduced T cell numbers in the brain of CLEC12A^−/−^ mice ([Figure S4](#mmc1){ref-type="supplementary-material"}C). However, effector functions were markedly modulated in CLEC12A^−/−^ mice, as indicated by a reduced frequency of brain-sequestered T cells expressing GrB (21.3% ± 3.9% versus 34.4% ± 6.1%; [Figure 4](#fig4){ref-type="fig"}C). Similar results were obtained for splenic T cells; frequencies of GrB^+^ CD4^+^ T cells (6.0% ± 1.1% versus 10.5% ± 1.2%) and CD8^+^ T cells (13.9% ± 2.0% versus 22.1% ± 2.2%) were significantly reduced in CLEC12A^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}D).

In conclusion, these findings demonstrate that CLEC12A affects ECM development by enhancing T cell effector functions; namely, GrB expression by activated CD8^+^ T cells.

Discussion {#sec3}
==========

Hemozoin constitutes a *Plasmodium*-derived disposal product involved in immunomodulation during malaria ([@bib40]). However, little is known about the cellular receptors recognizing hemozoin. It has been proposed that hemozoin is bound by TLR9 ([@bib4]), likely by adsorbing *Plasmodium* DNA ([@bib34]), whereas the role of CLRs in hemozoin recognition has so far not been addressed. Recently, it has been reported that CLEC12A binds to uric acid crystals and subsequently regulates innate immune responses ([@bib28]). We thus hypothesized that the CLEC12A ligand present in *Plasmodium*-infected RBCs might be of crystalline origin. In this study, we identified CLEC12A as a receptor for hemozoin using CLR-hFc fusion proteins and CLEC12A-CD3 reporter cells.

Because T cells, as an important cell subset mediating ECM, depend on activation by APCs, several studies addressed the role of DCs in ECM pathogenesis. It has been demonstrated that conventional DCs are of crucial importance for cross-priming of brain-sequestered CD8^+^ T cells ([@bib8], [@bib23]). However, it is largely unknown how DCs detect *Plasmodium* antigens and parasite-derived products. There is growing evidence that PRRs play distinct roles in ECM pathogenesis *in vivo*, illustrated by previous findings regarding the effect of NLRs ([@bib9]) and TLRs ([@bib5], [@bib22], [@bib45]). In contrast, the role of CLRs in recognition of protozoan parasites has so far barely been addressed. In the present study, we observed a contribution of CLEC12A to hemozoin-dependent ROS production. Overall, PMA-induced ROS production by BMDCs was decreased upon hemozoin incubation, most prominently after 24 h. This is in agreement with previous findings where hemozoin has been reported to reduce ROS production in monocytes and macrophages, mainly after ingestion of the crystalline disposal product ([@bib3], [@bib39]). Interestingly, ROS production was significantly reduced in CLEC12A^−/−^ BMDCs compared with WT BMDCs, indicating that CLEC12A is involved in intracellular signaling leading to ROS production. [@bib28] reported critical involvement of CLEC12A in MSU-mediated respiratory burst by interfering with Syk signaling. Furthermore, moderate levels of ROS are critical for efficient T cell activation and effector functions; for instance, IL-2 production ([@bib10], [@bib27]). In a recent study, ROS was shown to be involved in cross-presentation of antigens to CD8^+^ T cells, where decreased ROS levels led to reduced CD8^+^ T cell responses ([@bib32]). DC-T cell co-culture assays revealed a marked contribution of the hemozoin/CLEC12A interaction to CD8^+^ T cell cross-priming. In particular, hemozoin-induced GrB and IL-2 production as well as the frequency of GrB^+^ and IL-2^+^ T cells were at least partly CLEC12A-dependent. IL-2 is known to positively regulate the expression of perforin and GrB in CD8^+^ T cells ([@bib16], [@bib44]). Furthermore, the CLEC12A/hemozoin interaction partially abrogated TNF-α production and the frequency of TNF-α-positive T cells *in vitro*.

Infection of susceptible mouse lines with PbA is a commonly used model for *Plasmodium*-induced inflammation and underlines the importance of CD8^+^ T cells for brain pathology via perforin- and GrB-dependent pathways ([@bib12], [@bib31], [@bib36]). To further investigate the role of the CLEC12A receptor in ECM pathology, CLEC12A^−/−^ mice were infected with PbA. CLEC12A^−/−^ mice displayed reduced ECM incidence and an ameliorated disease score, highlighting the crucial role of CLEC12A in PbA-mediated ECM development. However, this effect may not be exclusively mediated by the CLEC12A/hemozoin interaction. For instance, we cannot rule out that uric acid crystals or other endogenous CLEC12A ligands from damaged cells contribute to the *in vivo* effect of CLEC12A. Strikingly, GrB expression in brain-sequestered and splenic T cells was reduced in CLEC12A^−/−^ mice during PbA infection. These findings suggest that CLEC12A does not markedly affect overall T cell activation and brain sequestration but, rather, modulates the quality of the T cell response by altering GrB expression levels. Targeting CLEC12A on DCs increased the frequency of GrB^+^ T cells ([@bib48]). Interestingly, a recent study described a role of CLEC12A in induction of experimental autoimmune encephalomyelitis (EAE), where EAE disease induction was delayed and disease severity was reduced in CLEC12A^−/−^ mice ([@bib38]).

Taken together, our study shows that CLEC12A recognizes *Plasmodium*-derived hemozoin. In addition, CLEC12A is critically involved in the development of ECM during PbA infection. The CLEC12A/hemozoin interaction affected ROS production by DCs and cross-presentation of plasmodial antigens to CD8^+^ T cells. CLEC12A^−/−^ mice exhibited significantly decreased ECM incidence during PbA infection, accompanied by a reduced frequency of GrB-expressing T cells in both the brain and spleen ([Figure S4](#mmc1){ref-type="supplementary-material"}E). In summary, our findings demonstrate an important role of CLEC12A in hemozoin recognition and immune pathology during murine PbA infection. Future studies should further investigate the role of the CLEC12A/hemozoin interaction *in vivo*; for instance, by using other murine malaria models.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Goat anti-human IgG (Fc) APJackson ImmunoResearch LabsCAT\#109-055-008; RRID:[AB_2337601](nif-antibody:AB_2337601){#intref0010}Goat anti-human IgG (Fc) PEJackson ImmunoResearch LabsCAT\#109-115-098; RRID:[AB_2337675](nif-antibody:AB_2337675){#intref0015}Goat anti-human IgG (Fc) Alexa Fluor 488Jackson ImmunoResearch LabsCAT\#109-545-098; RRID:[AB_2337840](nif-antibody:AB_2337840){#intref0020}Rat anti-mouse CD16/32eBioscience (Thermo Fisher Scientific)CAT\#14-0161-86; RRID:[AB_467135](nif-antibody:AB_467135){#intref0025}Rat anti-mouse CD4 APC-eFluor^®^780eBioscience (Thermo Fisher Scientific)CAT\#47-0042-82; RRID:[AB_1272183](nif-antibody:AB_1272183){#intref0030}Armenian hamster anti-mouse CD11c APCeBioscience (Thermo Fisher Scientific)CAT\#17-0114-82; RRID:[AB_469346](nif-antibody:AB_469346){#intref0035}Mouse anti-mouse MHC-II FITCeBioscience (Thermo Fisher Scientific)CAT\#11-5320-82; RRID:[AB_2572501](nif-antibody:AB_2572501){#intref0040}Rat anti-mouse CD86 PEeBioscience (Thermo Fisher Scientific)CAT\#12-0862-83; RRID:[AB_465769](nif-antibody:AB_465769){#intref0045}Rat anti-mouse CD4 FITCeBioscience (Thermo Fisher Scientific)CAT\#11-0041-85; RRID:[AB_464893](nif-antibody:AB_464893){#intref0050}Rat anti-mouse CD8a PEBD BioscienceCAT\#561095; RRID:[AB_2034011](nif-antibody:AB_2034011){#intref0055}Rat anti-mouse CD62L PE-Cy7eBioscience (Thermo Fisher Scientific)CAT\#25-0621-82; RRID:[AB_469633](nif-antibody:AB_469633){#intref0060}Armenian hamster anti-mouse CD69 APCeBioscience (Thermo Fisher Scientific)CAT\#17-0691-82; RRID:[AB_1210795](nif-antibody:AB_1210795){#intref0065}Rat anti-mouse CD8a FITCeBioscience (Thermo Fisher Scientific)CAT\#11-0081-82; RRID:[AB_464915](nif-antibody:AB_464915){#intref0070}Rat anti-mouse Granzyme B APCeBioscience (Thermo Fisher Scientific)CAT\#17-8898-82; RRID:[AB_2688068](nif-antibody:AB_2688068){#intref0075}Rat anti-mouse IL-2 APCeBioscience (Thermo Fisher Scientific)CAT\#17-7021-82; RRID:[AB_469490](nif-antibody:AB_469490){#intref0080}Rat anti-mouse TNF-α APCeBioscience (Thermo Fisher Scientific)CAT\#17-7321-82; RRID:[AB_469508](nif-antibody:AB_469508){#intref0085}Rat anti-mouse IFN-γ APCBD BioscienceCAT\#554413; RRID:[AB_398551](nif-antibody:AB_398551){#intref0090}Rat anti-mouse CLEC12A PEBioLegendCAT\#143403; RRID:[AB_11126747](nif-antibody:AB_11126747){#intref0095}Rat anti-mouse CD4 FITCMiltenyi BiotecCAT\#130-091-608; RRID:[AB_244286](nif-antibody:AB_244286){#intref0100}Rat anti-mouse CD8a APCMiltenyi BiotecCAT\#130-091-606; RRID:[AB_244291](nif-antibody:AB_244291){#intref0105}Hamster anti-mouse CD69 PerCP-Cy5.5eBioscience (Thermo Fisher Scientific)CAT\#45-0691-82; RRID:[AB_1210703](nif-antibody:AB_1210703){#intref0110}Rat anti-mouse CD8 APC-H7BD BioscienceCAT\#560182; RRID:[AB_1645237](nif-antibody:AB_1645237){#intref0115}Rat anti-mouse CD45 PerCPMiltenyi BiotecCAT\#130-094-962; RRID:[AB_10828455](nif-antibody:AB_10828455){#intref0120}Rat anti-mouse CD62L PEMiltenyi BiotecCAT\#130-091-794; RRID:[AB_244290](nif-antibody:AB_244290){#intref0125}**Chemicals, Peptides, and Recombinant Proteins**C-type lectin receptor Fc fusion proteins[@bib25], [@bib26], [@bib28]N/ApFuse-hIgG1-FcInvivoGenCAT\#pfuse-hg1fc2Freestyle CHO Expression mediumFisher ScientificCAT\#10546183Freestyle MAX reagentFisher ScientificCAT\#10259172HemozoinInvivogenCAT\#tlrl-hz7-AAD viability staining solutioneBioscience (Thermo Fisher Scientific)CAT\#00-6993-50Phorbol-12-myristate-13-acetate (PMA)AppliChemCAT\#A0903,0001Dihydrorhodamine (DHR)-123Sigma-AldrichCAT\#D1054-2MGOVA-AlexaFluor 488Thermo Fisher ScientificCAT\#O34781DQ™ OVAThermo Fisher ScientificCAT\#D12053LPSSigma-AldrichCAT\#L4391-1MGEndoGrade^®^ ovalbuminHyglosCAT\#321001GolgiPlugBD BiosciencesCAT\#555029IonomycinSigma-AldrichCAT\#I0634-1MG**Critical Commercial Assays**Murine TNF-α Standard ABTS ELISA Development KitPeproTechCAT\#900-K54Murine IL-12 Standard ABTS ELISA Development KitPeproTechCAT\#900-K97Murine IL-2 Standard ABTS ELISA Development KitPeproTechCAT\#900-K108Murine IFN-γ Standard ABTS ELISA Development KitPeproTechCAT\#900-K98Granzyme B Mouse Uncoated ELISA KitThermo Fisher ScientificCAT\#88-8022-88; RRID: [AB_2575171](nif-antibody:AB_2575171){#intref0130}Pan T Cell Isolation Kit II mouseMiltenyi BiotecCAT\# 130-095-130**Experimental Models: Cell Lines**mCLEC12A, hCLEC12A, mCLEC7A A5 T cell hybridoma reporter cell lines[@bib28]N/A**Experimental Models: Organisms/Strains**CLEC12A^−/−^ mice[@bib28]N/AOT-I C57BL/6-Tg(TcraTcrb)1100Mjb/Crl miceCharles RiverCAT\#642OT1OT-II C57BL/6-Tg(TcraTcrb)425Cbn/J miceown breedingN/A**Oligonucleotides**Primer for CLEC12A genotyping: WT-Fw: 5′-CTGTATGCCCTTAATACACCTCCTGC-3′[@bib28]N/AKO-Fw: 5'-GGTGGGATTAGATAAATGCCTGC-3′[@bib28]N/ARv: 5'-CCATGAACAATGAGGAGAGAAGCC-3′[@bib28]N/A**Software and Algorithms**GraphPad Prism Version 7GraphPad SoftwareN/AFlowJo Version 10FlowJo LLCN/A

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and request for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Bernd Lepenies (<Bernd.Lepenies@tiho-hannover.de>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mouse model {#sec4.3.1}

The generation of CLEC12A^−/−^ mice was described previously and mice were backcrossed to C57BL/6 background for ten generations ([@bib28]). The genotype of the CLEC12A^−/−^ mice was confirmed by PCR (WT-Fw: 5′-CTGTATGCCCTTAATACACCTCCTGC-3′; KO-Fw: 5'-GGTGGGATTAGATAAATGCCTGC-3′; Rv: 5'-CCATGAACAATGAGGAGAGAAGCC-3′) and flow cytometric analysis of spleen and bone marrow cells using PE-conjugated anti-mouse CLEC12A antibody (5D3/CLEC12A, BioLegend, San Diego, CA, 1:200). Mice were kept and bred in the animal facility of the Federal Institute for Risk Assessment (Berlin, Germany) under specific pathogen-free conditions and provided food and water *ad libitum*. Female CLEC12A^−/−^ mice or the respective C57BL/6 wild-type control mice were used for PbA infection experiments at 6-10 weeks of age and maintained on a 12:12 hr light-dark cycle. Experiments were permitted by the Ethics Commission of the Institutional Animal Care and Use Committee (IACUC) of the Regional Office for Health and Social Affairs Berlin under reference numbers G0053/10 and G0198/14 and/or the German Lower Saxony State Office for Consumer Protection and Food Safety under reference number 33.12-42502-04-15/1936. All efforts were made to minimize suffering. Sacrificing of mice for scientific purposes was approved by the Animal Welfare Officers of the University of Veterinary Medicine Hannover (AZ 02.05.2016).

### Primary cell culture {#sec4.3.2}

Bone marrow cells were obtained from femur and tibia of CLEC12A^−/−^ and C57BL/6 control mice (own breeding) and were differentiated into BMDCs using differentiation medium (IMDM medium, 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin 100 μg/ml streptomycin, 10% X63-GM-CSF supernatant) at 37°C and 5% CO~2~ for 8 to 10 days. Mice used for bone marrow extraction were not restricted to a specific age or gender. They were maintained under specific pathogen-free conditions on a 12:12 hr light-dark cycle in the animal facility of the Institute for Physiological Chemistry of the University of Veterinary Medicine Hannover, Foundation.

Method Details {#sec4.4}
--------------

### Culture of *Plasmodium* species {#sec4.4.1}

The *Plasmodium falciparum* 3D7 line was cultured in human erythrocytes (0+) from healthy donors. Cultures were maintained at a hematocrit of 2.7% in 3D7 culture medium (RPMI 1640, 0.5% Albumax II, 5 mM HEPES, 2 mM L-glutamine, 28 μg/ml hypoxanthine, 50 μg/ml gentamicin). Cultures were incubated in an anaerobic jar flushed with a gas mixture of 95% N~2~, 5% CO~2~, and 2% O~2~ at 37°C. Medium was replaced daily and parasitemia was estimated by Giemsa staining of thin blood smears. Parasitemia was routinely kept at 1%--10%. Cultures were synchronized by incubating parasites every 96 hours with 5% D-sorbitol for 10min ([@bib20]).

The PbA strains 1008M and MRA-311 were kindly provided by PD Dr. Thomas Jacobs (Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany). Stabilates were prepared by passage through BALB/c mice. Parasitized RBCs were snap frozen in 0.9% NaCl, 4.2% D-sorbitol, and 28% glycerol and used for subsequent infection experiments.

### CLR-hFc binding assays {#sec4.4.2}

Lysates of *Plasmodium*-infected RBCs were derived from synchronized late-stage parasites by magnetic activated cell sorting. Blood obtained from PbA-infected BALB/c mice was diluted in PBS and loaded onto an LD column (Miltenyi Biotec, Bergisch Gladbach, Germany). The column was washed with MACS buffer (PBS, 1% BSA, 2mM EDTA), followed by elution of infected cells ([@bib46]). Purity of late-stage parasites was confirmed by Giemsa staining of thin blood smears and RBCs were subsequently lysed with ultrapure water.

The generation of the CLR-hFc fusion protein library was described previously ([@bib25], [@bib26]). Sequences encoding the extracellular domain of indicated CLRs were ligated into the expression vector pFuse-hIgG1-Fc (InvivoGen, San Diego, CA). Constructs were subsequently used to transiently transfect CHO-S cells using the FreeStyle Max CHO-S Expression System (Life Technologies, Darmstadt, Germany) or for generation of stable CLR-hFc expressing CHO cells. Soluble fusion proteins were purified from the supernatant by affinity chromatography using protein G columns (GE Healthcare, Little Chalfont, UK). Purity and identity were confirmed by SDS-PAGE and hFc-specific western blot, respectively.

For ELISA-based binding assays, lysates of *Plasmodium*-infected RBCs were coated on high-binding 96-well microtiter ELISA plates (Greiner Bio-One, Kremsmünster, Austria) at RT overnight, corresponding to 2.5 × 10^5^ pRBCs per well. The next day, wells were blocked using 1% BSA in PBS for 2h at RT, followed by the addition of CLR-hFc fusion proteins at 5 μg/ml in lectin buffer/BSA (50 mM HEPES, 0.5% BSA, 5 mM CaCl~2~, 5 mM MgCl~2~, pH 7.4) for 2h at RT. Binding was detected after incubation with AP-conjugated anti-human IgG (Fc) antibody (MinX, Jackson ImmunoResearch Labs, Cambridgeshire, UK) 1:5000 in reagent diluent (1% BSA, 0.05% Tween 20 in PBS) and colorimetric detection using pNPP as substrate. After each step, plates were washed with 0.05% Tween 20^®^ in PBS.

Synthetic hemozoin (InvivoGen) was incubated for 2h at 4°C with indicated hFc-fusion proteins in DMEM containing 10% FBS, washed with PBS 1% FBS and bound hFc-fusion proteins were stained with anti-human IgG (Fc)-PE (MinX, Jackson ImmunoResearch Labs) 1:100 in 0.5% PBS/BSA for 30min at 4°C. PE fluorescence of hemozoin particles was analyzed by flow cytometry. To confirm CLEC12A-hFc binding to hemozoin in the presence of higher protein concentrations, selected experiments were also performed DMEM containing 20% FBS and 50% FBS, respectively (data not shown).

### Fluorescence microscopy {#sec4.4.3}

PbA-infected RBCs were fixed in 1% PFA for 10min at RT with subsequent permeabilization with 0.1% saponin in lectin binding buffer (50 mM HEPES, 1% BSA, 5 mM CaCl~2~, 5 mM MgCl~2~, pH 7.4) for 10min at RT. RBCs were stained with the indicated fusion proteins at 5μg/ml in saponin-supplemented lectin binding buffer for 2h at 4°C followed by incubation with an anti-human IgG (Fc) Alexa Fluor 488-labeled antibody (Jackson ImmunoResearch Labs) in saponin-supplemented 1% FBS in PBS (1:200 dilution) for 1h at 4°C. Stained samples were applied to poly-L-lysine-coated cover slides for 90min at 37°C and mounted into proLong™ Gold antifade mountant containing DAPI (Invitrogen). Fluorescence was detected using a TCS SP5 confocal inverted-base fluorescence microscope (Leica, Nussloch, Germany).

Synthetic hemozoin (InvivoGen) was incubated with the indicated hFc-fusion proteins at 10 μg/ml in DMEM 10% FBS for 2h at 4°C. Binding was detected using an anti-human IgG (Fc) Alexa Fluor 488-labeled antibody (Jackson ImmunoResearch Labs) diluted 1:200 in 1% FBS in PBS for 2h at 4°C. Samples were applied to microscopic slides and mounted into Eukitt^®^ quick hardening mounting medium (Sigma-Aldrich, St. Louis, MO). Fluorescence was detected using an Axio Imager M2 microscope (Zeiss, Oberkochen, Germany).

### Scanning electron microscopy {#sec4.4.4}

Crystals were applied to 12,7 mm SEM stubs (Science Services, München, Germany) and gold sputtered using a Q150R-S sputter coater (Quorum Technologies, Laughton, UK) for 240 s at a sputter current of 20 mA and a tooling factor set to 2.30. Samples were transferred directly to a Crossbeam 540 KMAT SEM (Zeiss, Oberkochen, Germany) equipped with a thermic Schottky-emitter, using a sample lock. Imaging was done at 10 kV acceleration voltage at a magnification of 15.000x and a chamber vacuum of 3 × 10^−6^ mBar, using a Everhart-Thornley chamber secondary electron detector. Scan speed was set to step 11, probe current was 500 pA.

### Reporter cell line assay {#sec4.4.5}

A5 T cell hybridoma reporter cell lines expressing murine CLEC7A, murine CLEC12A and human CLEC12A, respectively ([@bib28]), were cultured in selection medium (RPMI 1640, 5% FBS, 2 mM L-glutamine, 1 mg/ml G418) at 37°C and 5% CO~2~. On day 4, reporter cells were transferred to assay medium (RPMI 1640, 0.5% FBS, 2 mM L-glutamine). Cells were seeded in a 96-well plate at a concentration of 8 × 10^5^ cells/ml and stimulated with MSU (250 μg/ml), hemozoin (100 μg/ml, InvivoGen), lysates of parasitized RBCs (ratio 20:1) and lysates of uninfected RBCs (ratio 20:1) at 37°C and 5% CO~2~ for 18h. Afterward, cells were blocked with anti-mouse CD16/32 (93, eBioscience, Frankfurt am Main, Germany, 1:100) for 10min at 4°C and stained with anti-mouse CD4 APC-eFluor^®^780 (RM4-5, eBioscience, 1:200) as a reporter cell staining for 20min at 4°C. 7-AAD (eBioscience, 1:80) was used as a viability staining for 15min at RT. GFP expression of stained cells was analyzed by an Attune NxT Flow Cytometer (Thermo Fisher Scientific, Waltham, MA). Data analysis was performed using FlowJo (Version 10, FlowJo LLC., Ashland, OR).

### ROS assay {#sec4.4.6}

Bone marrow cells were obtained from femur and tibia of CLEC12A^−/−^ and C57BL/6 control mice (own breeding) and were differentiated into BMDCs using differentiation medium (IMDM medium, 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin 100 μg/ml streptomycin, 10% X63-GM-CSF supernatant) at 37°C and 5% CO~2~. After 8 to 10 days of differentiation, BMDCs were seeded at a concentration of 5 × 10^5^ cells/ml in a 96-well plate and incubated with hemozoin (100 μg/ml, InvivoGen) at 37°C and 5% CO~2~ for 4h or 24h. Cells were stimulated with PMA (100 ng/ml, AppliChem, Darmstadt, Germany) for 15min followed by addition of dihydrorhodamine (DHR)-123 (0.5 μg/ml, Sigma-Aldrich) for 15min at 37°C and 5% CO~2~. Cells were blocked with anti-mouse CD16/32 (93, eBioscience, 1:100) for 10min at 4°C and stained with APC-conjugated anti-mouse CD11c (N418, eBioscience, 1:200) for 20min at 4°C. ROS production was analyzed using an Attune NxT Flow Cytometer (Thermo Fisher Scientific).

### OVA uptake and processing {#sec4.4.7}

Bone marrow cells were differentiated as described above (ROS assay). After 8 to 10 days of differentiation, BMDCs were seeded at a concentration of 5 × 10^5^ cells/ml in a 96-well plate and stimulated with OVA-Alexa Fluor 488 (25 μg/ml, Thermo Fisher Scientific) or DQ™ OVA (25 μg/ml, Thermo Fisher Scientific) in the presence or absence of hemozoin (50, 20 μg/ml, InvivoGen) at 37°C and 5% CO~2~ for 45min. Subsequently, cells were blocked with anti-mouse CD16/32 (93, eBioscience, 1:100) for 10min at 4°C and stained with APC-conjugated anti-mouse CD11c (N418, eBioscience, 1:200) for 20min at 4°C. Samples were analyzed by an Attune NxT Flow Cytometer (Thermo Fisher Scientific).

### DC stimulation assay {#sec4.4.8}

Bone marrow cells were differentiated as described above (ROS assay). After 8 to 10 days of differentiation, BMDCs were seeded at a concentration of 5 × 10^5^ cells/ml in a 96-well plate and stimulated with LPS (1 ng/ml, Sigma-Aldrich) in the presence or absence of hemozoin (100, 50 μg/ml, InvivoGen) at 37°C and 5% CO~2~ for 24h. On the next day, supernatants were harvested and cytokine concentrations were measured by ELISA (Murine TNF-α Standard ABTS ELISA Development Kit, Murine IL-12 Standard ABTS ELISA Development Kit, PeproTech, Hamburg, Germany). BMDCs were blocked with anti-mouse CD16/32 (93, eBioscience, 1:100) for 10min at 4°C and stained with APC-conjugated anti-mouse CD11c (N418, eBioscience, 1:200), FITC-conjugated anti-mouse MHC-II (AF6-120.1, eBioscience, 1:100) and PE-conjugated anti-mouse CD86 (B7-2, eBioscience, 1:200) for 20min at 4°C. Samples were analyzed using an Attune NxT Flow Cytometer (Thermo Fisher Scientific).

### DC-T cell co-culture assay {#sec4.4.9}

Bone marrow cells were differentiated as described above (ROS assay). After 8 to 10 days of differentiation, BMDCs were seeded at a concentration of 2 × 10^5^ cells/ml in a 96-well plate and stimulated with EndoGrade^®^ ovalbumin (0.3 mg/ml, Hyglos, Bernried, Germany) in the presence or absence of hemozoin (100, 50, 20 μg/ml, InvivoGen) at 37°C and 5% CO~2~ for 24h. T cells were isolated from spleens of 8 to 14 week old OT-I (purchased from Charles River, Sulzfeld, Germany) and OT-II (own breeding) transgenic mice via magnetic-activated cell sorting (Pan T Cell Isolation Kit II mouse, Miltenyi Biotec). Purified T cells were adjusted to 1 × 10^6^ cells/ml and co-cultured with BMDCs at 37°C and 5% CO~2~ overnight or for 72h, respectively.

After overnight incubation, intracellular granzyme B, IL-2, TNF-α and IFN-γ levels were determined upon restimulation of T cells with PMA (100 ng/ml, AppliChem)/Ionomycin (1 μg/ml, Sigma-Aldrich) in the presence of GolgiPlug (1 μl/ml, BD Biosciences) at 37°C and 5% CO~2~ for 3h. Cells were blocked with anti-mouse CD16/32 (93, eBioscience, 1:100) for 10min at 4°C and stained using FITC-conjugated anti-mouse CD8a (53-6.7, eBioscience, 1:100) for 20min at 4°C followed by fixation with 1% PFA for 20min at RT. Subsequently, cells were permeabilized with saponin buffer (0.5% saponin, 1% FBS in PBS) for 10min at RT and stained for intracellular cytokines with APC-conjugated anti-mouse granzyme B (NGZB, eBioscience), anti-IL-2 (JES6-5H4, eBioscience), anti-TNF-α (MP6-XT22, eBioscience) or anti-IFN-γ (XMG1.2, BD Biosciences, Franklin Lakes, NJ), respectively, diluted 1:200 in permeabilization buffer for 20min at RT. Samples were analyzed using an Attune NxT Flow Cytometer (Thermo Fisher Scientific).

After 72h of incubation, supernatants were harvested and GrB, IL-2, TNF-α and IFN-γ cytokine concentrations were measured by ELISA (Granzyme B Mouse Uncoated ELISA Kit, Thermo Fisher Scientific, Murine IL-2 Standard ABTS ELISA Development Kit, Murine TNF-α Standard ABTS ELISA Development Kit, Murine IFN-γ Standard ABTS ELISA Development Kit, PeproTech). Lymphocytes were blocked with anti-mouse CD16/32 (93, eBioscience, 1:100) for 10min at 4°C and either stained with FITC-conjugated anti-mouse CD4 (RM4-5, eBioscience, 1:100) or PE-conjugated anti-mouse CD8a (53-6.7, BD Bioscience, 1:200) and PE-Cy7-conjugated anti-mouse CD62L (MEL-14, eBioscience, 1:200) as well as APC-conjugated anti-mouse CD69 (H1.2F3, eBioscience, 1:200) for 20min at 4°C. Samples were analyzed using an Attune NxT Flow Cytometer (Thermo Fisher Scientific).

### Challenge of mice with PbA {#sec4.4.10}

Female CLEC12A^−/−^ mice or the respective C57BL/6 wild-type control mice were intraperitoneally injected with 1 × 10^6^ PbA-infected RBCs ([@bib21], [@bib24]). Body weight and clinical score were monitored during the course of infection, accompanied by daily monitoring for early signs of ECM (more often during ECM development between day 7 and day 10 p.i.). Disease scoring was performed as described previously ([@bib7]). C57BL/6 mice infected with PbA develop general symptoms such as ruffled fur and hunching as well as ECM-specific symptoms including wobbly gait, convulsions, and limb paralysis. Each symptom was assigned a score of 1. Mice were euthanized at an early stage of ECM to minimize suffering (cumulative score of 3-4). For each following day post sacrifice, a score of 5 was assigned. Parasitemia was determined by examining Giemsa-stained thin blood smears obtained from the tail vein. Parasitemia was denoted as the percentage of pRBCs.

### Flow cytometric analysis of T cells {#sec4.4.11}

Splenocytes and brain-sequestered T cells were analyzed by flow cytometry. Mice infected with PbA were sacrificed on day 6 p.i. Spleens were dissected and flushed with complete RPMI (RPMI 1640, 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin). Collected cells were treated with RBC lysis buffer (144 mM NH~4~Cl, 10 mM Tris-HCl, pH 7.2) at RT for 5min. Splenocytes were incubated with anti-mouse CD16/32 (93, eBioscience, 1:100) for 20min at 4°C and stained using anti-mouse CD4 FITC (GK1.5, Miltenyi Biotec, 1:100), anti-mouse CD8a APC (53-6.7, Miltenyi Biotec, 1:100), and anti-mouse CD69 PerCP-Cy5.5 (H1.2F3, eBioscience, 1:100) for 30min at 4°C. Intracellular granzyme B levels were determined after incubation of splenocytes in complete RPMI supplemented with 1 μl/ml GolgiPlug (BD Biosciences) at 37°C and 5% CO~2~ for 3h. Cells were incubated with anti-mouse CD16/32 (93, eBioscience, 1:100) for 20min at 4°C and stained using anti-mouse CD4 FITC (GK1.5, Miltenyi Biotec, 1:200) and anti-mouse CD8 APC-H7 (53-6.7, BD Biosciences, 1:200) for 30min at 4°C. To access intracellular GrB, cells were fixed in 2% PFA in PBS for 20min at RT, permeabilized using 0.5% saponin for 10min at RT, and stained with APC-conjugated anti-mouse granzyme B antibody (NGZB, eBioscience, 1:100) for 30min at 4°C.

Brain sequestration of T cells in PbA-infected mice was investigated using brain homogenates. Brains were isolated from PbA infected mice on day 6 p.i. and homogenized in complete RPMI and filtered through a cell strainer (40 μm). After lysis of RBCs, brain homogenates were blocked with anti-mouse CD16/32 (93, eBioscience, 1:100) for 20min at 4°C and stained with anti-mouse CD45 PerCP (30F11, Miltenyi Biotec, 1:50), anti-mouse CD62L PE (MEL14-H2.100, Miltenyi Biotec, 1:50) and anti-mouse CD8 APC-H7 (53-6.7, BD Biosciences, 1:50) for 30min at 4°C. Intracellular GrB levels of brain homogenates were assessed as described above ([@bib24]).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

All statistical analyses were performed using the GraphPad Prism software (Version 7, La Jolla, CA). For PbA infections, Kaplan-Meyer survival curves were analyzed using the log-rank (Mantel-Cox) test. Time courses for disease score, body weight, and parasitemia were compared by two-way ANOVA. All other data was analyzed by unpaired or paired Student's t test. To exclude hemozoin-independent intrinsic effects between WT and CLEC12A^−/−^ DCs (ROS assay, OVA uptake and processing, DC-T cell co-culture assays), data was normalized to the respective positive controls and depicted as fold increase or percentage in relation to control. In [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [S1--S3](#mmc1){ref-type="supplementary-material"}, n represents the number of biological replicates. In the PbA infection experiments ([Figures 4](#fig4){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}), n represents the number of animals. Statistical details, including biological and technical replicates and animal numbers, are provided in the respective figure legends. A *p-value* of p \< 0.05 was considered statistically significant.
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